Latest Breaking News On - Strategic equity investment - Page 1 : comparemela.com

EV Stock Breaking News: NIO Inc (NYSE: NIO) Announces US$2 2 Billion Strategic Equity Investment from CYVN

EV Stock Breaking News: NIO Inc. (NYSE: NIO) Announces US$2.2 Billion Strategic Equity Investment from CYVN

Hong kongJassem al zaabiAbu dhabiLtd the investorSingapore exchange securities tradingLike renewable energy stocksStock exchange of hong kongExchange commissionDecember investment transactionSecurities actDecember investmentManaging directorAutonomous drivingSecurities litigation reform actStock exchangeHong kong limited

Global Blue Completes Strategic Equity Investment and Entry Into New Credit Agreement

Global Blue Completes Strategic Equity Investment and Entry Into New Credit Agreement
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongFrances gibbonsTencent fintechGlobal blue group holdingPartners groupExchange commissionStrategic equity investmentGlobal blueNet debtSilver lakeTax free shoppingFree shoppingTax freeMain boardStock exchangeAnnual report

EV Company News For The Month Of July 2023

EV Company News For The Month Of July 2023
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomUnited statesNew yorkNew zealandFrance generalNoord hollandBruxelles capitaleMexico cityDistrito federalSoult ukpyolsiSouth koreaSaudi arabiaHong kongAbu dhabiAbuz aby

OrthoNebraska takes private equity investment from InTandem Capital Partners

Omaha-based OrthoNebraska and InTandem Capital Partners completed a strategic equity investment, the firm said Aug. 2.

Elliot cooperstoneOmaha based orthonebraskaIntandem capital partnersIntandem capitalIntandem capital partnersStrategic equity investmentElliot cooperstoneHigh qualityCost effective carePatient outcomesLower costsPatient experienceSuperior care

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular

Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease

United kingdomUnited statesPatrickj mcenanyDavid schull russoDrug administrationEuropean medicines agencyMoelis companyInvestor contact mary coleman catalyst pharmaceuticals incLife science allianceChiesi groupJapan should santhera pursue partnership opportunitiesSteering committeeHealth canadaCatalyst pharmaceuticalsSanthera pharmaceuticals holdingCatalyst pharmaceuticals inc